Agilent Technologies acquires specific assets of A2 Technologies

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Feb 10 2011Agilent Technologies Inc.

Agilent Technologies Inc. (NYSE: A) has completed the acquisition of specific assets of A2 Technologies. Financial details were not disclosed for the acquisition, which was first announced Jan. 19.

The acquisition supports Agilent's goal of expanding its spectroscopy business. Substantially all of A2 Technologies' intellectual property, technology and spectroscopy product portfolio are now part of Agilent's Spectroscopy Solutions Division within its Chemical Analysis Group. All former A2 Technologies employees have joined Agilent.

Source:

Agilent Technologies Inc.

Posted in: Business / Finance

Tags: , ,

Comments (0)

Suggested Reading

Ramadan fasting linked to favorable metabolic changes and reduced chronic disease risk
Fentanyl Identification On the Street and In the Lab
Newly identified helicase might hold the key to a novel family of anti-COVID-19 drugs
Targeted ocular spectroscopy shines new light on retinal health
Revolutionizing diabetes management with reliable blood glucose monitoring without finger pricking
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology
Exploring the benefits of walnut flour in gluten-free bread
Rapid identification of disease-causing bacteria using Raman spectroscopy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study unveils previously unknown urinary biomarkers, revolutionizing early detection and treatment of viral infections like COVID-19